- Hookipa Pharma ( NASDAQ: HOOK ) has been awarded a $10M milestone payment under a collaborative R&D deal with Roche ( OTCQX:RHHBY ) ( OTCQX:RHHBF ).
- The drug developer is working on HB-700, a novel arenaviral immunotherapy for KRAS-mutated cancers. The milestone payment was triggered with the start of production of HB-700 to support a phase 1 clinical trial.
- Hookipa ( HOOK ) is aiming to submit an Investigational New Drug Application to the FDA in H1/2024. It has been working on HB-700 since October 2022.
- Under the collaboration, Hookipa ( HOOK ) is eligible for R&D and commercialization milestone-based payments of up to $930M.
- Shares of the biopharmaceutical company climbed ~3% premarket on Monday
For further details see:
Hookipa Pharma gets $10M milestone payment from Roche